• 1
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97107.
  • 2
    World Health Organization. Hepatitis B Fact Sheet No. 204, Revised August 2008. WHO: World Health Organization, Geneva, Switzerland.
  • 3
    Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 6612.
  • 4
    European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 22742.
  • 5
    Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 101120.
  • 6
    Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 100110.
  • 7
    Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 143744.
  • 8
    Yokosuka O, Takaguchi K, Fujioka S et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52: 7919.
  • 9
    Tenney DJ, Pokornowski KA, Rose RE et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009; 50 (Suppl. 1): S10.
  • 10
    Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 88693.
  • 11
    Lampertico P, Viganò M, Facchetti F et al. Effectiveness of entecavir for NUC-naive, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients. J Hepatol 2010; 52 (Suppl. 1): S389.
  • 12
    Lampertico P, Viganò M, Soffredini R et al. Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience. Hepatology 2010; 52 (Suppl. 1): S514A.
  • 13
    Lim SG, 2, Aung MO, Sutedja D et al. Outcomes of treatment for chronic hepatitis B with entecavir therapy. Hepatology 2010; 52 (Suppl. 1): S537A.
  • 14
    Lampertico P, Viganò M, Yurdaydin C et al. Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B. Hepatology 2010; 52 (Suppl. 1): S503A.
  • 15
    Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006; 13: 78798.
  • 16
    Seale JP, Gebski VJ, Keech AC. Generalizing the results of trials to clinical practice. Med J Aust 2004; 181: 55860.